MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
What will happen during the trial?
This trial is anticipated to open to US patients in April 2023
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 3
- Enrollment
- 1,590 patients (estimated)
- Sponsors
- Janssen Research & Development LLC
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1312
- NCT Identifier
- NCT05552222
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.